Department of Obstetrics and Gynecology, Leiden University Medical Center, Leiden, The Netherlands; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Department of Obstetrics and Gynecology, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia.
Gynecol Oncol. 2018 Jan;148(1):189-196. doi: 10.1016/j.ygyno.2017.10.009. Epub 2017 Nov 4.
To investigate the prevalence of somatic mutations in Indonesian cervical carcinoma patients in the context of histology and human papillomavirus (HPV) type.
In total 174 somatic hot-spot mutations in 13 genes were analyzed by mass spectrometry in 137 Indonesian cervical carcinomas.
In 66/137 tumors (48%) 95 mutations were identified. PIK3CA was most frequently mutated (24%), followed by FBXW7 (7%), CTNNB1 (6%), and PTEN (6%). In squamous cell carcinomas more often multiple mutations per sample (p=0.040), and more PIK3CA (p=0.039) and CTNNB1 (p=0.038) mutations were detected compared to adenocarcinomas. PIK3CA mutations were associated with HPV 16 positivity, CDKN2A mutations with HPV 52 positivity, and, interestingly, PTEN mutations with HPV negativity. Balinese tumor samples more often carried multiple mutations (p=0.019), and more CTNNB1, CDKN2A, and NRAS mutations compared to Javanese tumor samples.
Potentially targetable somatic mutations occurred in 48% of Indonesian cervical carcinomas. The landscape of mutations is predominated by mutations concerning the PI3K pathway, and we prompt for more research on developing therapies targeting this pathway, explicitly for the more advanced stage cervical carcinoma patients.
在组织学和人乳头瘤病毒(HPV)类型的背景下,调查印度尼西亚宫颈癌患者体细胞突变的流行情况。
通过质谱法在 137 例印度尼西亚宫颈癌中分析了 13 个基因中的 174 个体细胞热点突变。
在 66/137 例肿瘤(48%)中鉴定出 95 个突变。PIK3CA 突变最常见(24%),其次是 FBXW7(7%)、CTNNB1(6%)和 PTEN(6%)。与腺癌相比,鳞癌中每个样本的突变更多(p=0.040),并且检测到更多的 PIK3CA(p=0.039)和 CTNNB1(p=0.038)突变。PIK3CA 突变与 HPV 16 阳性相关,CDKN2A 突变与 HPV 52 阳性相关,有趣的是,PTEN 突变与 HPV 阴性相关。巴厘岛肿瘤样本比爪哇肿瘤样本更常携带多个突变(p=0.019),并且更常携带 CTNNB1、CDKN2A 和 NRAS 突变。
在 48%的印度尼西亚宫颈癌中发生了潜在可靶向的体细胞突变。突变的格局以涉及 PI3K 通路的突变为主,我们强烈呼吁开展更多针对该通路的治疗方法的研究,特别是针对更晚期的宫颈癌患者。